Adicon Holdings (HKG:9860) is acquiring 100% equity interests in Yuande Weikang and Yuande Youqin for a total consideration of approximately 229.2 million yuan (HK$241 million), paid through a mix of new shares and cash.
The deal includes issuing up to 29 million new shares or 4% of Adicon's enlarged capital for Yuande Weikang and a 50 million yuan cash payment for Yuande Youqin, with part of the share consideration tied to performance milestones.
Yuande Weikang specializes in hematological diagnostic reagents, while Yuande Youqin focuses on medical testing services, aligning with Adicon's strategy to expand its independent clinical laboratory (ICL) network and enhance vertical integration.
The acquisition is classified as a discloseable transaction under Hong Kong Listing Rules, requiring no shareholder approval, but completion remains subject to regulatory and financial conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.